The Bayer Cross

SAFYRAL® combines
YASMIN® (drospirenone 3 mg /ethinyl estradiol 0.03 mg)
with levomefolate calcium, a B vitamin

30 mcg EE + 3 mg drsp* + 451 mcg levomefolate calcium

SAFYRAL provides an approach to help folate supplementation become a part of her daily oral contraception (OC) routine

  • The Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommend that all women of childbearing age supplement their diet with at least 400 mcg of folic acid daily to reduce the risk of a neural tube defect (NTD) affected pregnancy1,2*
  • Counsel patients to report whether they are taking folate supplements. Ensure that folate supplementation is maintained if a woman discontinues SAFYRAL

SAFYRAL ALSO provides an approach to help folate supplementation become a part of her daily oral contraception (OC) routine

SAFYRAL AND YASMIN are indicated for women who choose an OC for contraception for:

  • Prevention of pregnancy
    • 99% contraceptive efficacy when taken as directed

ALSO, SAFYRAL is indicated for women who choose an OC for contraception to:

  • Raise folate levels for the purpose of reducing the risk of a NTD in a pregnancy conceived while taking the product or shortly after discontinuing the product
    • SAFYRAL is not indicated for use during pregnancy
    • Plasma folate levels are likely to return to baseline ~20 weeks after discontinuation
    • Folates may mask vitamin B12 deficiency

SAFYRAL is available in pharmacies and Bayer Savings Cards are available to your patients. Please see www.BayerSavingsCard.com for full program details and restrictions.

Important Safety Information About SAFYRAL and YASMIN, Including Boxed Warning

Patients who should not take SAFYRAL or YASMIN

Women over 35 years old who smoke should not use SAFYRAL or YASMIN. Smoking increases the risk of serious cardiovascular side effects from SAFYRAL or YASMIN use. This risk increases with age and the number of cigarettes smoked.

Know serious risks with SAFYRAL and YASMIN

Serious adverse reactions in clinical trials:

Most common adverse reactions (≥2%) in clinical trials:

Drug interactions (see Prescribing Information of concomitant drugs)

Please see full Prescribing Information about SAFYRAL, including boxed warning.

Please see full Prescribing Information about YASMIN, including boxed warning.

* The health authorities cited do not endorse specific products or brands.

1. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR. 1992;41(RR-14):1-7.
2. U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:626-631.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.